Mouse Anti-FN3K Recombinant Antibody (4F2) (CBMAB-A3059-LY)

Minnaert, A. K., van Schie, L., Grootaert, H., Himpe, J., Devos, S., Weyts, W., ... & Remaut, K. (2022). Yeast-produced fructosamine-3-kinase retains mobility after ex vivo intravitreal injection in human and bovine eyes as determined by Fluorescence Correlation Spectroscopy. International Journal of Pharmaceutics, 621, 121772.

Yousefi, T., Pasha, A. R. G., Kamrani, G., Ebrahimzadeh, A., Zahedian, A., Hajian-Tilaki, K., ... & Qujeq, D. (2021). Evaluation of Fructosamine 3-kinase and Glyoxalase 1 activity in normal and breast cancer tissues. BioMedicine, 11(3), 15.

De Bruyne, S., van Schie, L., Himpe, J., De Somer, F., Everaert, I., Derave, W., ... & Delanghe, J. R. (2021). A potential role for fructosamine-3-kinase in cataract treatment. International journal of molecular sciences, 22(8), 3841.

Beeraka, N. M., Bovilla, V. R., Doreswamy, S. H., Puttalingaiah, S., Srinivasan, A., & Madhunapantula, S. V. (2021). The taming of nuclear factor erythroid-2-related factor-2 (Nrf2) deglycation by fructosamine-3-kinase (FN3K)-inhibitors-a novel strategy to combat cancers. Cancers, 13(2), 281.

Szwergold, B. (2021). A Hypothesis: Fructosamine-3-Kinase-Related-Protein (FN3KRP) catalyzes deglycation of maillard intermediates directly downstream from fructosamines. Rejuvenation Research, 24(4), 310-318.

Shrestha, S., Katiyar, S., Sanz-Rodriguez, C. E., Kemppinen, N. R., Kim, H. W., Kadirvelraj, R., ... & Kannan, N. (2020). A redox-active switch in fructosamine-3-kinases expands the regulatory repertoire of the protein kinase superfamily. Science signaling, 13(639), eaax6313.

Sartore, G., Ragazzi, E., Burlina, S., Paleari, R., Chilelli, N. C., Mosca, A., ... & Lapolla, A. (2020). Role of fructosamine-3-kinase in protecting against the onset of microvascular and macrovascular complications in patients with T2DM. BMJ Open Diabetes Research and Care, 8(1), e001256.

De Bruyne, S., Van den Broecke, C., Vrielinck, H., Khelifi, S., De Wever, O., Bracke, K., ... & Delanghe, J. R. (2020). Fructosamine-3-kinase as a potential treatment option for age-related macular degeneration. Journal of clinical medicine, 9(9), 2869.

Sanghvi, V. R., Leibold, J., Mina, M., Mohan, P., Berishaj, M., Li, Z., ... & Wendel, H. G. (2019). The oncogenic action of NRF2 depends on de-glycation by fructosamine-3-kinase. Cell, 178(4), 807-819.

Dunmore, S. J., Al-Derawi, A. S., Nayak, A. U., Narshi, A., Nevill, A. M., Hellwig, A., ... & Singh, B. M. (2018). Evidence that differences in fructosamine-3-kinase activity may be associated with the glycation gap in human diabetes. Diabetes, 67(1), 131-136.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols